論文

2010

Tachibana T, Kitamura S, Kato M, Mitsui T, Shirasaka Y, Yamashita S, Sugiyama Y. Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm Res. 2010 Mar;27(3):442-6.
Uchimura T, Kato M, Saito T, Kinoshita H. Prediction of human blood-to-plasma drug concentration ratio. Biopharm Drug Dispos. 2010 Jul;31(5-6):286-97.
Ito T, Kato M, Chiba K, Okazaki O, Sugiyama Y. Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature. Drug Metab Pharmacokinet. 2010;25(3):243-53.
Kato M, Chiba K, Ito T, Koue T, Sugiyama Y. Prediction of interindividual variability in pharmacokinetics for CYP3A4 substrates in humans. Drug Metab Pharmacokinet. 2010;25(4):367-78.
Kaneko A, Kato M, Endo C, Nakano K, Ishigai M, Takeda K. Prediction of clinical CYP3A4 induction using cryopreserved human hepatocytes. Xenobiotica. 2010 Dec;40(12):791-9

2009

Tachibana T, Kato M, Watanabe T, Mitsui T, Sugiyama Y. Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica. 2009 Jun;39(6):430-43.
加藤基浩、杉山雄一 バイオ医薬品のMD・早期探索臨床試験の展望 ─投与量設定と薬物動態─ 医薬品評価 2009 Vol36:589-603
Kaneko A, Kato M, Sekiguchi N, Mitsui T, Takeda K, Aso Y In vitro model for the prediction of clinical CYP3A4 induction using HepaRG cells. Xenobiotica. 2009 Nov;39(11):803-10.
Sekiguchi N, Higashida A, Kato M, Nabuchi Y, Mitsui T, Takanashi K, Aso Y, Ishigai M. Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. Drug Metab Pharmacokinet. 2009;24(6):500-10.


2008

Kato M, Shitara Y, Sato H, Yoshisue K, Hirano M, Ikeda T, Sugiyama Y. The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling. Pharm Res. 2008 Aug;25(8):1891-901.
Kato M Intestinal first pass metabolism for CYP3A4 substrates Drug Metab Pharmacokinet. 2008;23(2):87-94
Sekiguchi N, Kato M, Takata M, Watanabe, Sakai S, Ishigai M, Aso Y In vivo approach for the evaluation of mechanism-based inhibition of cytochrome P450 3A in rats. Xenobiotica. 2008 Apr;38(4):368-81
Uchimura T, Kato M, Saito K, Kinoshita H. Estimation of serum protein binding of compounds metabolized in serum using matrix inhibition. Biopharm Drug Dispos. 2008 Jul;29(5):308-10.
Uchimura T, Kato M, Tachibana T, Arai S, Nabuchi Y, Saito K, Kinoshita H. New method for the simultaneous estimation of intrinsic hepatic clearance and protein binding by matrix inhibition Biopharm Drug Dispos. 2008 Jan;29(1):7-16
東純一、加藤基浩、岡崎彬 健康成人を対象としたニコランジルの単回+持続静脈内投与時の安全性および薬物動態の検討 薬理と治療 36 supple.1 s15-S24
杉山雄一、馬屋原宏、池田敏彦他 早期探索臨床試験(マイクロドーズ試験を除く)実施に関する指針 医薬品評価 2008 Vol35:633-650
矢野恒夫、杉山雄一、加藤基浩他 ペプチド・タンパク質のマイクロドーズ臨床試験の意義・実施基盤 医薬品評価 2008 Vol35:651-665


2005

Kato, M., Chiba, K., Horikawa, M., and Sugiyama Y The quantitative prediction of enzyme-induction caused by drug exposures from in vitro information with human hepatocytes to in vivo Drug Metabol. Pharmacokin. 20: 2005

2003

Kato, M., Tachibana, T.,  Ito, K and Sugiyama Y Evaluation of the prediction methods for drug-drug interaction by Monte Carlo simulation Drug Metabol. Pharmacokin. 18:121-127, 2003
Kato, M., Chiba, K., Hisaka, A., Ishigami, M., Kayama, M.,  Mizuno, N., Nagata, Y., Takakuwa, S., Tsukamoto, T.,  Ueda, U., Kusuhara, H., Ito , K., and Sugiyama Y The intestinal first pass metabolism of the substrates for CYP3A4 and P-glycoprotein - Quantitative analysis based on the literature information Drug Metabol. Pharmacokin. 18:, 2003

2002

Ito, K., Chiba, K., Horikawa, M., Ishigami, M., Mizuno, N., Aoki, J.,  Gotoh, Y., Iwatsubo, T., Kanamitsu, S., Kato, M., Kawahara, I., Niinuma, K., Nishino, A., Sato, N., Tsukamoto, Y., Ueda,K., Itoh, T and Sugiyama Y Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS PharmSci, 2002

 2001

Kato, M., Okano, K., Sakamoto, Y., Miura, K., Uchimura, T. and Saito K. Pharmacokinetics and Pharmacodynamics of recombinant human erythropoietin in rats Arzneim.-Forsch/Drug Res, 51: 91-95, 2001

 1999

Kato, M., Kato, Y. and Sugiyama, Y. Mechanism of the upregulation of erythropoietin-induced uptake clearance by the spleen Am J Physiol, 276: E887-95
Kato, M., Kato, Y., Nakamura, T. and Sugiyama, Y. Efficient extraction by the liver governs overall elimination of hepatocyte growth factor in rats J Pharmacol Exp Ther, 290: 373-9

1998

Kato, M., Miura, K., Kamiyama, H., Okazaki, A., Kumaki, K., Kato, Y. and Sugiyama, Y. Pharmacokinetics of erythropoietin in genetically anemic mice Drug Metab Dispos, 26: 126-31

1997

Kato, M., Kamiyama, H., Okazaki, A., Kumaki, K., Kato, Y. and Sugiyama, Y. Mechanism for the Nonlinear pharmacokinetics of Erythropoietin in Rats.  J Pharmacol Exp Ther, 283: 520-527
Kato, M., Miura, K., Kamiyama, H., Okazaki, A., Kumaki, K., Kato, Y. and Sugiyama, Y. Immunological response to repeated administration of recombinant human erythropoietin in rats: biphasic effect on its pharmacokinetics Drug Metab Dispos, 25: 1039-44
Liu, K. X., Kato, Y., Kato, M., Kaku, T. I., Nakamura, T. and Sugiyama, Y. Existence of two nonlinear elimination mechanisms for hepatocyte growth factor in rats Am J Physiol, 273: E891-7
Kato, M. エリスロポエチン(EPO) 薬局, 48(5), 759-763

1996

Sugiyama, Y., Kato, M. and Ito, K. 医薬品開発におけるファーマコキネティクス研究の役割1 ( 薬物動態の基礎(1)) ファームテクジャパン: 12(19), 7-16

1995

Nakagawa, T., Ishigai, M., Kato, M., Hayakawa, N., Kinoshita, H., Okutomi, T., Ohkubo, K. and Okazaki, A.  Pharmacokinetics of the New Fluoroquinolone Balofloxacin in Mice, Rats and Dogs Arzbeimittel-Forschung/Drug Resesrch 45, 719-722
Kato, M., Miura, K., Kamiyama, H. and Okazaki, A. 高分子薬物の皮下投与後の体内動態-rG-CSFを中心にして 薬物動態, 10(1), 56-64

1994

Kato, M., Miura, K., Kamiyama, H.. and Okazaki, A. 遺伝子組換えヒト型エリスロポエチン(EPOCH)皮下投与後の体内動態(4) 薬理と治療, 22(3), 1349-1356
Kato, M., Miura, K., Kamiyama, H.. and Okazaki, A. ラットにおけるEPOCH注製剤の含量間生物学的同等性試験 基礎と臨床, 28(3), 719-723
Amano, J., Hiramatsu, Y., Okano, K., Kato, M., Kinoshita, H. and Okazaki, A. rG・CSFの体内動態(5)-ラットにおける125I-rG・CSF単回静脈内あるいは皮下投与時の排泄 薬理と治療, 22(1), 445-460
Hiramatsu, Y., Amano, J., Okano, K., Kato, M., Kinoshita, H. and Okazaki, A. rG・CSFの体内動態(6)-ラットにおける125I-rG・CSF反復静脈内あるいは皮下投与時の排泄 薬理と治療, 22(1), 461-466
Ohishi, N., Tokura, S., Amano, J., Kato, M., Hiramatsu, Y., Iida, S., Okano, K., Takata, S., Kinoshita, H. and Okazaki, A. rG・CSFの体内動態(7)-ラット肝ミクロゾーム薬物代謝酵素系に対する影響 薬理と治療, 22(1), 467-472

1993

Kato, M., Niwa, K., Kamiyama, H., Ohkubo, K. and Okazaki, A. 遺伝子組換えヒト型エリスロポエチン(EPOCH)皮下投与後の体内動態(1) 薬物動態, 8(4), 471-479
Kato, M., Niwa, K., Amano, J., Hayakawa, N., Kamiyama, H., Ohkubo, K. and Okazaki, A. 遺伝子組換えヒト型エリスロポエチン(EPOCH)皮下投与後の体内動態(2) 薬物動態, 8(4), 481-492
Kato, M., Niwa, K., Amano, J., Hayakawa, N., Kamiyama, H., Ohkubo, K. and Okazaki, A. 遺伝子組換えヒト型エリスロポエチン(EPOCH)皮下投与後の体内動態(3) 薬物動態, 8(4), 493-503

1992

Tatsumi, K., Kitamura, S., Kato, M. and Hiraoka, K. Metabolism of sodium nifrustyrenate, a veterinary antimicrobial nitrofuran, in animals and fish Drug metabolim and disposition 20, 226-233
Kinoshita, H., Ohishi, N., Kato, M. and Okazaki, A. Pharmacokinetics and distribution of recombinant erythropoietin in rats Arzbeimittel-Forschung/Drug Resesrch 42, 174-178
Kinoshita, H., Ohishi, N., Kato, M.., Tokura, S. and Okazaki, A. Distribution of recombinant human erythropoietin following multiple intravenous administration and effects of age on the distribution in rats Arzbeimittel-Forschung/Drug Resesrch 42, 579-584

1991

Kinoshita, H., Ohishi, N., Kato, M.., Tokura, S. and Okazaki, A. Comparative pharmacokinetics and distribution of human urinary erythropoietin and recombinant human erythropoietin in rats Arzbeimittel-Forschung/Drug Resesrch 42, 579-584


1990

Kinoshita, H., Tokura, S., Ohishi, N., Ichikawa, H., Kato, M., Iida, S., ., Shimizu, T., Mizuno K. and Okazaki, A. rh-EPOの体内動態(1)-ラット、イヌにおけるrh-EPOの血漿中濃度推移および尿中排泄 臨床医薬, 6 suppl.2, 578-584
Kinoshita, H., Ohishi, N., Kato, M., Iida, S., Ichikawa, H. and Okazaki, A. rh-EPOの体内動態(2)-ラットにおけるrh-EPOの排泄動態 臨床医薬,  6 suppl.2, 585-590
Kinoshita, H., Tokura, S., Ohishi, N., Kato, M., Iida, S.,  Okazaki, A. and Backer, S.J. rh-EPOの体内動態(3)-ラットにおける125I-rh-EPOの胎仔および乳汁中移行 臨床医薬, 6 suppl.2, 591-597
Kinoshita, H., Ohishi, N., Hiramatsu, Y., Kato, M.,  Ichikawa, H. and Okazaki, A. rh-EPOの体内動態(4)-ラットにおける125I-rh-EPO静脈内反復投与時の体内分布 臨床医薬, 6 suppl.2, 598-606
Kinoshita, H., Kato, M., Amano J., Hiramatsu, Y., Okano, K., Ohishi, N., Okazaki, A., Tatsumi, T., Koto, M. and Adachi J. rG・CSFの体内動態(1)-ラット、イヌ、サルにおけるrG・CSFの血中動態(単回) 薬理と治療, 18 suppl.9, S2615-S2623
Kinoshita, H., Kato, M., Amano J., Hiramatsu, Y., Okano, K. and Okazaki, A. rG・CSFの体内動態(2)-rG・CSF反復投与時のラットにおける血中動態 薬理と治療, 18 suppl.9, S2625-S2628
Kinoshita, H., Ichihara, T., Ohishi, N., Tokura, S., Amano, J., Kato, M., Okano, K. and Okazaki, A. rG・CSFの体内動態(4)-ラットにおける125I-recombinant human G-CSF(125I-rG・CSF)の胎仔移行およびrG・CSFの乳汁中移行 薬理と治療, 18 suppl.9, S2641-S2651